A Phase 1/2, Open-label Trial to Evaluate Safety, Immunogenicity, and Anti-tumor Activity of VB10.16 in Combination with Pembrolizumab in Patients with Unresectable Recurrent or Metastatic HPV16-positive Head and Neck Squamous Cell Carcinoma (VB-C-03)

Principal Investigator

Dr Ketan Shah

Contact us

Email: latephaseoncology@ouh.nhs.uk

IRAS number

1007089